BACKGROUND: Polymorphism in promoter region can change the expression of genes, which may be associated with susceptivity of diseases. Gene polymorphism of interleukin-6 (IL-6) promoter is associated with nationality and many diseases. Different nationalities often display different characteristics of gene polymorphism.OBJECTIVE: To observe the distribution of polymorphism at sites -597 and -572 in IL-6 promoter region in Tibet Tibetan population and to provide the theoretical data for Tibetan population genetics and background of immunity.DESIGN: Randomized investigation.SETTING: Institute of Anthropology, Jinzhou Medical College.PARTICIPANTS: Totally 108 healthy Tibetan teenagers were selected from Lasa and Naqu region in Tibet autonomous region from October 2003 to July 2004, including 60 males and 48 females, aged from 14-21 years. Inclusive criteria:The parents of the volunteers were healthy Tibetans after body examination. The volunteers knew the fact, agreed to participate into the trail and signed the informed consent.METHODS: 5 mL peripheral vein blood was collected from 108 Tibetan teenagers. DNA from human leucocytes was extracted by salt fractionation. IL-6 promoter including -597 and -572 fragments was amplified by polymerase chain reaction (PCR). Representative fragments were cloned then sequenced after restriction fragment length polymorphism (RFLP).MAIN OUTCOME MEASURES: Distribution of polymorphism in Tibet Tibetan population; Results after comparison with those of other nationalities including Han population.RESULTS: Data of 108 Tibetan teenagers were involved in the result analysis. ①Distribution of polymorphism on -572C/G site of IL-6 promoters in population of either sex: There were no GA and AA genotypes at site -597, but only GG genotype appeared. There were CC, CG and GG genotypes at site -572, and the frequencies were 0.63, 0.35 and 0.02 in order. Distribution of genotype with representativeness met the Hardy-Weinberg equilibrium. Allele frequencies were 0.81 and 0.19, respectively. There was no significant difference of either sex in genotype and allele frequency (P ＞ 0.05). ②Distribution of polymorphism on -597 G/A and -572 C/G in different nationalities: GG, GA, AA genotypes appeared on -597 site in England and France, and G and A allele frequencies were 0.60 and 0.40,respectively. It was significantly different from that of Tibetan in Tibet. Furthermore, Japanese had no polymorphism,which was similar to that of Hans in China (P ＞ 0.05). ③Genotype of different straps and results of DNA sequencing:Only GG genotype was found on -597 site (without the restriction site, one fragment after restriction, PCR amplification products), no GA and AA genotypes. CC, CG and GG genotypes appeared at site -572, and frequencies were 0.64,0.35 and 0.01, respectively. Distribution of genotype with representativeness met the Hardy-Weinberg equilibrium (P ＞0.05). Allele frequencies were 0.81 and 0.19, respectively. There was no significant difference of either sex in genotype and allele frequency. Distribution of gene frequency and allele frequency in IL-6 were similar between Tibetan and that of Hans, but it was significantly different from that of population in England, France and America.CONCLUSION: There are nationality differences of IL-6 gene polymorphism at sites -597 and -572. No polymorphism is found at site -597 in Tibetan. Race differences are seen at site -572, having CC, CG and GG genotypes and G allele is rate. Compared with white population, there is significant difference in genotype and allele frequency at site -572. Their characteristics are close to Hah population and Japanese, which may be associated with genetic gene of persons living in plateau.

BACKGROUND: Soybean isoflavone has a variety of bioactivities and its antioxidation becomes a hot spot of research in recent years. At present,the research of soybean isoflavone places more emphasis on animal experiment and clinical observation,but lacks research on cellular level of human body.OBJECTIVE: To observe the influence of soybean isoflavone in vascular endothelial cells with oxidative damage.DESIGN: Controlled trial and observation.SETTING: Central Laboratory, Institute of Public Health,Tianjin Medical University.MATERIALS: The experiment was completed in the Central Laboratory,Institute of Public Health,Tianjin Medical University from January to July 2002.The experimental materials included vascular endothelial cell strain in human umbilical vein,low density lipoprotein,soybean isoflavone and vitamin E,etc.METHODS: The vascular endothelial cells were cultured in vitro.The experiment was divided into 6 groups: blank control group,oxidative damage control group (malondialdehyde content was 1 μmol/L),oxidative damage+vitamin E control group(vitamin E was 50 μmol/L) and oxidative damage+soybean isoflavone 10,50,100 μ mol/L control group. The endothelial cells,which were joined with vitamin E and soybean isoflavone of different concentrations in advance to be incubated for 24 hours,were affected by oxidized low density lipoproteins and then cultured continually for 24 hours.All the indexes of antioxidation were determined in both extra-cell and intra-cell.MAIN OUTCOME MEASURES: Malondialdehyde content,activity of superoxide dismutase and glutathione peroxidase,the release condition of lactate dehydrogenase and productive quantity of nitrogen monoxide inside and outside the endothelial cells of each group.RESULTS: ①Comparison of malondialdehyde content,the activity of superoxide dismutase and glutathione peroxidase in endothelial cells of each group: The malondialdehyde content was higher significantly in oxidative damage control group than in blank control group (P ＜ 0.01),but the activity of superoxide dismutase and glutathione peroxidase was lower significantly in oxidative damage control group than in blank control group(P ＜ 0.01).The malondialdehyde content was lower significantly in oxidative damage+vitamin E control group,oxidative damage+soybean isoflavone 10,50,100 μmol/L control group than in oxidative damage control group(P ＜ 0.01),but the activity of superoxide dismutase and glutathione peroxidase was higher significantly in oxidative damage+vitamin E control group,oxidative damage+soybean isoflavone 10,50,100 μ mol/L control group than in oxidative damage control group (P ＜ 0.01). ②Comparison of the release condition of lactate dehydrogenase and the productive quantity of nitrogen monoxide in endothelial cells of each group: The release percentage of lactate dehydrogenase was higher significantly in oxidative damage control group than in blank control group (P ＜ 0.01),but the productive quantity of nitrogen monoxide was lower significantly in oxidative damage control group than in blank control group(P ＜ 0.01).The release percentage of lactate dehydrogenase was lower significantly in oxidative damage+vitamin E control group,oxidative damage+soybean isoflavone 10,50,100 μmol/L control group than in oxidative damage control group (P ＜ 0.01),but the productive quantity of nitrogen monoxide was higher significantly in oxidative damage+vitamin E control group,oxidative damage+soybean isoflavone 10,50,100 μmol/L control group than in oxidative damage control group(P ＜ 0.01).CONCLUSION: Soybean isoflavone can alleviate the oxidative damage in vascular endothelial cells,caused by oxidized low density lipoprotein,possibly through such antioxidization indexes as malondialdehyde content,the activity of superoxide dismutase and glutathione peroxidase,the release condition of lactate dehydrogenase and the productive quantity of nitrogen monoxide,etc.

OBJECTIVE:To establish a method for simultaneous determination of ephedrine hydrochloride,nitrofural and di-phenhydramine hydrochloride in Compound diphenhydramine nasal drop. METHODS:RP-HPLC method was adopted. The determi-nation was performed on Inertsil ODS-3 C18 column with mobile phase consisted of 0.05 mol/L potassium dihydrogen phosphate buf-fer(pH 7.0)-acetonitrile(gradient elution)with flow rate of 1.0 mL/min. The detection wavelength was set at 256 nm,and the col-umn temperature was 35 ℃. The sample size was 20 μL. RESULTS:The concentrations of phedrine hydrochloride,nitrofural and diphenhydramine hydrochloride ranged 122.1-366.3 μg/mL(r=0.9999),5.2-15.5 μg/mL(r=0.9998)and 31.5-94.5 μg/mL(r=0.9994),respectively. The limits of quantitation were 2.442,0.010,2.520 μg/mL,and the limits of detection were 0.810,0.003, 0.830 μg/mL,respectively. RSDs of precision,stability and reproducibility tests were lower than 1.0%. The recoveries of them were 99.2%-101.7%(RSD=0.9%,n=9),96.4%-102.0%%(RSD=1.7%,n=9),100.2%-101.9%(RSD=0.4%,n=9),respec-tively. CONCLUSIONS:The method is simple,accurate and reproducible,and can be used for simultaneous determination of ephedrine hydrochloride,nitrofural and diphenhydramine hydrochloride in Compound diphenhydramine nasal drop.

A recurrent misdiagnosed case of congenital left renal arteriovenous fistula (RAVF) with multiple left renal arteries and scoliosis was reported. The patient was admitted to hospital on 29 August 2020 due to repeated hematuria for one year. No abnormality was found in two flexible ureteroscope examinations, imaging and laboratory examinations after admission. It was found that the structure of blood vessels in the inferior pole of renal sinus was disordered, and the blood vessels were tortuous and clustered through careful reading of CT enhancement films. The dilated tortuous blood vessels were also seen around the renal pelvis, and hematuria was considered to be caused by renal vascular malformation. In order to confirm the etiology, digital subtraction angiography (DSA) of renal artery was performed. DSA showed a congenital left renal RAVF with three renal arteries, and the arteriovenous fistula of renal arteries was embolized. For patients presenting with severe gross hematuria, if tumor, stone, tuberculosis, or coagulation abnormalities were excluded by conventional imaging and/or laboratory examination the possibility of congenital renal vascular malformation should be suspected, and DSA examination should be performed. Endovascular embolization is an effective treatment for congenital RAVF.